2025 Japan Antibody Protection Revenue Opportunities Report
Description
The 2025 Japan Antibody Protection Revenue Opportunities Report features 1) market size data for the region or country, 2) annual market growth rates, 3) the market's impact on related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing, 4) Total Addressable Market (TOM) for the four largest market players, 5) Serviceable Addressable Market (SAM), and 6) Serviceable Obtainable Market (SOM)(Wharry Sharpe Research)
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in antibody protection and therapeutics in Japan include Takeda Pharmaceutical Company, Johnson & Johnson’s Janssen Pharmaceuticals, Cell Signaling Technology, and Abcam. Takeda collaborates with ImmunoGen to develop antibody-drug conjugates like ELAHERE for ovarian cancer, highlighting its commitment to innovative oncology therapies in Japan. Janssen gained approval for DARZALEX SC, a subcutaneous antibody treatment for multiple myeloma, enhancing patient convenience compared to intravenous formulations. Cell Signaling Technology leads Japan’s antibody supplier market with a 22.7% share, closely followed by Abcam with 17.6%, dominating the supply of primary and secondary antibodies.
Beyond these, other notable companies contributing to antibody research in Japan include Invitrogen Antibodies, MilliporeSigma, and Santa Cruz Biotechnology, although some show declining market shares. Additionally, Japanese biotech firms such as Chiome Bioscience, RevolKa, and Ribomic are innovating in monoclonal antibodies and protein engineering using AI technologies, supporting domestic advancements in antibody drug discovery and development. The market landscape is further shaped by global pharmaceutical giants like Roche, AstraZeneca, and Novartis that are expanding bispecific antibody research targeting cancer and autoimmune diseases in Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
The Revenue Opportunities Reports provide market size data for a three-year historical trend (2019-2022), a three-year forecast estimate trends (2023-2025), and a five-year outlook projection (2026-2031) for the region or country. The report also features written analysis on market definitions, and market segments.
Market and product shipments include the total value of all products produced and shipped by all producers (also described as value of receipts, value of production, or value of work done.)
The report features written analysis and market size statistics on opportunities created in the Antibody Protection by the changing related industries Medical and Surgical Hospitals, Offices of Physicians, and Medical Device Manufacturing,
The four largest companies actively involved in antibody protection and therapeutics in Japan include Takeda Pharmaceutical Company, Johnson & Johnson’s Janssen Pharmaceuticals, Cell Signaling Technology, and Abcam. Takeda collaborates with ImmunoGen to develop antibody-drug conjugates like ELAHERE for ovarian cancer, highlighting its commitment to innovative oncology therapies in Japan. Janssen gained approval for DARZALEX SC, a subcutaneous antibody treatment for multiple myeloma, enhancing patient convenience compared to intravenous formulations. Cell Signaling Technology leads Japan’s antibody supplier market with a 22.7% share, closely followed by Abcam with 17.6%, dominating the supply of primary and secondary antibodies.
Beyond these, other notable companies contributing to antibody research in Japan include Invitrogen Antibodies, MilliporeSigma, and Santa Cruz Biotechnology, although some show declining market shares. Additionally, Japanese biotech firms such as Chiome Bioscience, RevolKa, and Ribomic are innovating in monoclonal antibodies and protein engineering using AI technologies, supporting domestic advancements in antibody drug discovery and development. The market landscape is further shaped by global pharmaceutical giants like Roche, AstraZeneca, and Novartis that are expanding bispecific antibody research targeting cancer and autoimmune diseases in Japan.
Revenue Opportunities are defined by the measurements of Total Addressable Market (TOM) for the four largest market players, Serviceable Addressable Market (SAM), and Serviceable Obtainable Market (SOM). The measurements include both written analysis and current calculations for each company in the market for each country or region.
This report does not provide the names of companies in the market or written analysis of each market's trends within each country to provide a cost-effective report that focuses solely on the statistics and data on each market.
Wharry Sharpe Research publishes thousands of market analysis and product research report annually to assist their clients with the essential data they need for the market research, budgeting and forecasting needs.
Table of Contents
51 Pages
- A. Definitions
- A1. Market Definition
- A2. Market Segmentation
- A3. Industry Opportunities-Industry1
- A4. Industry Opportunities-Industry2
- A5. Industry Opportunities-Industry3
- B. Total Addressable Market (TAM)
- B1. TAM-Player 1/4
- B2. TAM-Player 2/4
- B3. TAM-Player 3/4
- B4. TAM-Player 4/4
- C. Serviceable Addressable Market (SAM)
- C1. SAM-Player 1/4
- C2. SAM-Player 2/4
- C3. SAM-Player 3/4
- C4. SAM-Player 4/4
- D. Serviceable Obtainable Market (SOM)
- D1. SOM-Player 1/4
- D2. SOM-Player 2/4
- D3. SOM-Player 3/4
- D4. SOM-Player 4/4
- E. Appendix
Search Inside Report
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
